SDH-deficient gastrointestinal stromal tumors: paradoxical effect of imatinib

Cover Page


Succinate dehydrogenase deficient gastrointestinal stromal tumors (dSDH GIST) is a unique group of GISTs with an energy metabolism defect as the key oncogenic mechanism without mutations in the proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor a (PDGFRA). SDH-deficiency is a result of mutations in SDHA, SDHB, SDHC, SDHD. There are three variants of dSDH GIST: sporadic dSDH GIST, Carney triad or Carney-Stratakis syndrome. dSDH GISTs are characterized by young age, female prevalence, gastric location, multiple tumors, lymph node metastases, indolent behavior and poorly response to imatinib. Despite the literature data, we report the response to imatinib in patient with dSDH GIST. 21 year old female patient presented with incomplete Carney triad (multiply gastric GIST with liver and peritoneal metastases, left lung chondroma). The patient received imatinib with clinical response in a month and radiological response in three months-cystic transformation of primary gastric tumor and liver metastases. The duration of response was 8 months.

Full Text

Restricted Access

About the authors

Daria A. Filonenko

Blokhin National Medical Research Center of Oncology

Author for correspondence.
ORCID iD: 0000-0002-7224-3111

Russian Federation, Moscow

Cand. Sci. (Med.)

Andrey A. Meshcheryakov

Blokhin National Medical Research Center of Oncology

ORCID iD: 0000-0002-6009-653X

Russian Federation, Moscow

D. Sci. (Med.)

Petr P. Arkhiri

Blokhin National Medical Research Center of Oncology


Russian Federation, Moscow

Cand. Sci. (Med.)

Maxim P. Nikulin

Blokhin National Medical Research Center of Oncology

ORCID iD: 0000-0002-9608-4696

Russian Federation, Moscow

Cand. Sci. (Med.)

Evgeniia S. Kolobanova

Blokhin National Medical Research Center of Oncology


Russian Federation, Moscow



  1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279 (5350): 577–80.
  2. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438 (1): 1.
  3. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23 (23): 5357.
  4. Gill AJ, Chou A, Vilain R et al. Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types. Am J Surg Pathol 2010; 34 (34): 636–44.
  5. Boikos SA, Pappo AS, Killian JK et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016; 2 (7): 922–8.
  6. Miettinen M, Lasota J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – a review. Int J Biochem Cell Biology 2014; 53: 514–9.
  7. The Nobile Prize in Phisiology or Medicine 1931.
  8. Selak MA, Armour SM et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-prolyl hydroxylase. Cancer Сell 2005; 7: 77–85.
  9. Pozza ED, Dando I, Pacchiana R et al. Regulation of succinate dehydrogenase and role of succinate in cancer. Semin Cell Dev Biol 2019: S1084-9521(19)30056-4.
  10. Eijkelenkamp K, Osinga T, Links T. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. Clin Genetics 2020; 97: 39–53.
  11. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009; 266 (1): 43–52.
  12. Haller F, Moskalev EA, Faucz FR. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014; 21 (4): 567–77. doi: 10.1530/ERC-14-0254
  13. Zhang L, Thomas C et al. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. Am J Surg Pathol 2010; 34 (1): 53–64.
  14. Ben-Ami E, Barysauskas CM, von Mehren M et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol 2016; 27 (9): 1794–9

Supplementary files

Supplementary Files Action
Fig. 1. Molecular genetic abnormalities in GIST.

Download (142KB) Indexing metadata
Fig. 2. Computed tomography (CT) data before the treatment: a – the tumor of the stomach (white arrow), a – liver metastases (red arrows); b – chondroma of the left lung (blue arrow).

Download (885KB) Indexing metadata
Fig. 3. Dynamic CT scanning against the background of applying imatinib: a, c – before the treatment, a – liver metastases, c – the tumor of the stomach (February 2019), b – after 2 months of therapy (April 2019) – cystic transformation of the liver metastases, d – after 2 months of therapy, cystic transformation of the tumor of the stomach.

Download (1MB) Indexing metadata



Abstract - 8

PDF (Russian) - 0





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies